Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia

CONTEXT: Burosumab was developed as a treatment option for patients with the rare, lifelong, chronically debilitating, genetic bone disease X-linked hypophosphatemia (XLH). OBJECTIVE: Collect additional information on the safety, immunogenicity, and clinical response to long-term administration of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Thomas J, Imel, Erik A, Carpenter, Thomas O, Peacock, Munro, Portale, Anthony A, Hetzer, Joel, Merritt, J Lawrence, Insogna, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759172/
https://www.ncbi.nlm.nih.gov/pubmed/36072994
http://dx.doi.org/10.1210/clinem/dgac518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759172/
https://www.ncbi.nlm.nih.gov/pubmed/36072994
http://dx.doi.org/10.1210/clinem/dgac518

Ejemplares similares